Page 5 of 62: studies 41 to 50 of 613, newest first. Back to the ibogaine overview
Substance Use & Misuse December 17, 2025 Markus D Moore, Andrew Moore, Saeed K Alzghari
Ibogaine is an interesting candidate that needs further study to determine its safety and potential for treating opioid dependence.
ACS Medicinal Chemistry Letters December 16, 2025 Anna C. Renner, Robert B. Kargbo
Emerging psychedelic therapeutics increasingly rely on mechanistic precision, receptor selectivity, and pharmacokinetic control. Recent inventions introduce simplified iboga analogs with tunable polypharmacology, real-time EEG biomarkers that individualize psilocybin dosing, and standardized harmine-DMT ratios with high bioavailability. Together, these innovations form a coherent framework for...
Frontiers in Pharmacology December 4, 2025 Maya Nicolas
This article proposes that ibogaine’s induction of GDNF, modulation of glutamate and dopamine signaling, and reopening of plasticity represent a unified mechanism capable of restoring reward system fidelity across disorders. This includes addiction, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and eating disorders, amongst others. These conditions are labelled as...
Journal of Affective Disorders November 18, 2025 Randi Brown, Jennifer I. Lissemore, Kenneth Shinozuka et al. 1 citation
Ibogaine is an atypical psychedelic that evokes unique subjective effects, including mystical experiences. Mystical experiences have shown a mediating effect on clinical improvements following treatment with several psychedelic substances; however, the relationship between mystical experiences and clinical outcomes following ibogaine remains unclear. We examined the association between mystical...
Research Square November 5, 2025 Joseph T. la Torre, Step Cheung, Ariana Kam et al. preprint
Abstract Drawing on an unprecedentedly larger sample (N = 236) than previous studies, we investigated the subjective effects of ibogaine by asking a series of three original, open-ended questions to participants enrolled in an ibogaine-assisted treatment program at a specialized healthcare facility in México. The objective was to characterize the overall phenomenology of the subjective ibogaine...
PLoS One October 13, 2025 Francisco González-espejito, Laura Esteban Rodríguez, Eduardo J. Pedrero Pérez et al.
Ibogaine, an indole alkaloid derived from the root bark of Tabernanthe iboga, has long been used in traditional Bwiti healing rituals and shows promise for treating opioid dependence and neurological conditions, but existing psychometric tools fail to capture its distinctive subjective/oneiric (dream-like) effects. To address this gap, we developed the 70-item Ibogaine Experience Scale (IES)...
Figshare October 13, 2025
Ibogaine, an indole alkaloid derived from the root bark of Tabernanthe iboga, has long been used in traditional Bwiti healing rituals and shows promise for treating opioid dependence and neurological conditions, but existing psychometric tools fail to capture its distinctive subjective/oneiric (dream-like) effects. To address this gap, we developed the 70-item Ibogaine Experience Scale (IES)...
Neuroscience October 5, 2025 Jannik Nicklas Eliasen, Amir Rezagholizadeh, Helene Påbøl Jacobsen et al. 1 citation
Depression and substance use disorder affect millions world-wide, and risk factors include sex. Conventional pharmacotherapies show at best a 50 % success rate. Psychedelics exhibit both anti-addictive and anti-depressive properties. One of these, ibogaine, a root bark sourced alkaloid, interacts with receptors implicated in anti-depressive and anti-addictive effects with affinities in the...
Journal of Medicine Surgery and Public Health August 25, 2025 R. Andrew Yockey 2 citations
Severe mental illness (SMI) and co-occurring substance use disorders (SUDs) continue to pose a major global health challenge, contributing to high rates of mortality, disability, and economic strain. Ibogaine, a naturally occurring psychoactive compound derived from the Tabernanthe iboga plant, has shown promise in easing withdrawal symptoms, reducing cravings, and improving psychiatric...
Progress in Neuro-Psychopharmacology and Biological Psychiatry August 1, 2025 Sofía Villalba, Sofia Bosch, Lucia di Constanzo et al. 1 citation
Noribogaine (Noribo) is the primary metabolite from ibogaine, an atypical psychedelic. The main objective of this study was to evaluate the effect of Noribo on thalamic physiology of calcium channels voltage activation and gene expression and the potential involvement of the 5-HT2A receptor on those effects. Thus, we used male and female, 5-HT2AR knockout (KO) and wild type (WT) mice, injected...